A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S. The ...

One of the best ways to defeat cancer is by rousing the immune system to attack it. Experts have thought that immune cells had to be inside of tumors for one type of immunotherapy, known as checkpoint ...

Experts at Cincinnati Children's report proof-of-concept results that may sharply reduce the risk of a lethal side effect that has negatively impacted the use of revolutionary cancer immunotherapies ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Subcutaneous immunotherapy injections for cancer, such as immune checkpoint inhibitors, are an emerging therapy that may replace some traditional intravenous infusions. Common side effects include ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S. The ...

Please provide your email address to receive an email when new articles are posted on . Roughly 20% of individuals treated with immune checkpoint inhibitors respond. Response rates began to plateau in ...

Immune checkpoint inhibitors are well known as a form of cancer treatment. Researchers at UZH have now identified a new, important function of these inhibitors: promotion of tissue healing. This ...

It often starts with something small—a dark spot on the skin that looks a little off. A dermatologist takes a closer look, runs a biopsy, and soon after, the diagnosis arrives: melanoma. If the cancer ...

A new study has revealed that autoantibodies—immune proteins traditionally associated with autoimmune disease—may profoundly influence how cancer patients respond to immunotherapy. Subscribe to our ...

Please provide your email address to receive an email when new articles are posted on . Glucocorticoids remain the primary option for immune-related adverse events of checkpoint inhibitor therapy in ...